144 related articles for article (PubMed ID: 19639164)
1. [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].
Hartmann H; Zöphel K; Freudenberg R; Oehme L; Andreeff M; Wunderlich G; Eisenhofer G; Kotzerke J
Nuklearmedizin; 2009; 48(5):201-7. PubMed ID: 19639164
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
3. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
4. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.
Sandström M; Velikyan I; Garske-Román U; Sörensen J; Eriksson B; Granberg D; Lundqvist H; Sundin A; Lubberink M
J Nucl Med; 2013 Oct; 54(10):1755-9. PubMed ID: 23929824
[TBL] [Abstract][Full Text] [Related]
5. Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT.
Beauregard JM; Croteau E; Ahmed N; van Lier JE; Bénard F
J Nucl Med; 2009 Jan; 50(1):100-7. PubMed ID: 19091905
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.
Hartmann H; Freudenberg R; Oehme L; Zöphel K; Schottelius M; Wester HJ; Wunderlich G; Kotzerke J; Brogsitter C
Nuklearmedizin; 2014; 53(5):211-6. PubMed ID: 25029274
[TBL] [Abstract][Full Text] [Related]
7. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
[TBL] [Abstract][Full Text] [Related]
8. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
9. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
10. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and radiation dose estimates for
Krebs S; Pandit-Taskar N; Reidy D; Beattie BJ; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; O'Donoghue JA
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):677-685. PubMed ID: 30374529
[TBL] [Abstract][Full Text] [Related]
12. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
15. 1-11C-methyl-4-piperidinyl-N-butyrate radiation dosimetry in humans by dynamic organ-specific evaluation.
Virta JR; Tolvanen T; Någren K; Brück A; Roivainen A; Rinne JO
J Nucl Med; 2008 Mar; 49(3):347-53. PubMed ID: 18287260
[TBL] [Abstract][Full Text] [Related]
16. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
[TBL] [Abstract][Full Text] [Related]
17. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
[TBL] [Abstract][Full Text] [Related]
18. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
[TBL] [Abstract][Full Text] [Related]
20. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]